10-Q

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2019

¨   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _________

Commission File No. 000-55114

CANFIELD MEDICAL SUPPLY, INC.

(Name of registrant in its charter)

Colorado	34-1720075
(State or other jurisdiction of incorporation or formation)	(I.R.S. employer identification number)

4120 Boardman-Canfield Road, Canfield, Ohio 44406

(Address of principal executive offices)

(330) 533-1914

(Registrant's telephone number, including area code) 

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

x Yes   ¨  No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

x Yes   ¨  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer", "smaller reporting company" and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer  ¨	Accelerated filer  ¨
Non-accelerated filer    ¨ (Do not check if a smaller reporting company)	Smaller reporting company  x Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

¨  Yes   x  No

Securities registered pursuant to Section 12(b) of the Act: None.

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.  As of May 20, 2019, there were 11,477,200 shares of Common Stock issued and outstanding.

CANFIELD MEDICAL SUPPLY, INC.

FORM 10-Q

March 31, 2019

TABLE OF CONTENTS

PART I.  FINANCIAL INFORMATION		Page
Item 1.	Condensed Financial Statements (Unaudited)	3
	Condensed Balance Sheets (Unaudited)	3
	Condensed Statements of Operations (Unaudited)	4
	Condensed Statements of Stockholders’ Equity (Deficit) (Unaudited)	5
	Condensed Statements of Cash Flows (Unaudited)	6
	Notes to Condensed Financial Statements (Unaudited)	7-13
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	14
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	16
Item 4.	Controls and Procedures	16
PART II.  OTHER INFORMATION		17
Item 1.	Legal Proceedings	17
Item 1A.	Risk Factors	17
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	17
Item 3.	Defaults Upon Senior Securities	17
Item 4.	Mine Safety Disclosures	17
Item 5.	Other Information	17
Item 6.	Exhibits	17
	Signatures	18

2 

PART I—FINANCIAL INFORMATION

Item 1.  Financial Statements.

CANFIELD MEDICAL SUPPLY, INC.

CONDENSED BALANCE SHEETS

(Unaudited)

	March 31,			December 31,
ASSETS	2019			2018
Current Assets
Cash	$	19,830		$	6,980
Accounts receivable		290,616			300,993
Inventory		24,963			41,695
Total Current Assets		335,409			349,668
Other Assets
Right-of-use asset		37,438			—
Equipment, net of accumulated depreciation of $88,664 and $92,907		49,107			58,627
Total Other Assets		86,545			58,627
Total Assets	$	421,954		$	408,295
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
Current Liabilities
Accounts payable and accrued liabilities	$	366,718		$	331,034
Line of credit		64,215			66,181
Current portion of long-term debt		5,926			8,241
Total Current Liabilities		436,859			405,456
Long-Term Liabilities
Lease liability		37,438			—
Long-term debt		4,652			5,498
Total Long-Term Liabilities		42,090			5,498
Total Liabilities		478,949			410,954
Stockholders' Equity (Deficit)
Preferred stock, no par value; 5,000,000 shares authorized; no shares
issued and outstanding		—			—
Common stock, no par value; 100,000,000 shares authorized;
11,477,200 shares issued and outstanding		245,515			245,515
Accumulated deficit		(302,510	)		(248,174	)
Total Stockholders' Equity (Deficit)		(56,995	)		(2,659	)
Total Liabilities and Stockholders' Equity (Deficit)	$	421,954		$	408,295

The accompanying footnotes are an integral part of these unaudited condensed financial statements.

3 

CANFIELD MEDICAL SUPPLY, INC.

CONDENSED STATEMENTS OF OPERATIONS

(Unaudited)

	Three months			Three months
	ended			ended
	March 31, 2019			March 31, 2018
Sales (net of returns)	$	271,955		$	344,624
Cost of goods sold		132,395			170,176
Gross profit		139,560			174,448
Operating expenses:
Salaries and wages		88,821			71,767
Professional fees		35,355			31,265
Depreciation		11,210			12,633
Other selling, general and administrative		52,252			42,830
Total operating expenses		187,638			158,495
Income (loss) from operations		(48,078	)		15,953
Other income (expense):
Interest expense		(1,342	)		(1,194	)
Gain (Loss) on sale of fixed assets		(4,916	)		5,249
Total other income (expense)		(6,258	)		4,055
Income (loss) before provision for income taxes		(54,336	)		20,008
Provision for income tax		—			—
Net income (loss)	$	(54,336	)	$	20,008
Net income (loss) per share (basic and fully diluted)		(0.00	)	$	0.00
Weighted average number of common shares outstanding		11,427,200			11,427,200

The accompanying footnotes are an integral part of these unaudited condensed financial statements.

4 

CANFIELD MEDICAL SUPPLY, INC.

CONDENSED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

(Unaudited)

	Common Stock (No Par)				Accumulated			Stockholders'
	Shares		Amount		Deficit			Equity (Deficit)
Balances at December 31, 2017		11,277,200	$	243,515	$	(316,380	)	$	(72,865	)
Net income		—		—		20,008			20,008
Balances at March 31, 2018		11,277,200	$	243,515	$	(296,372	)	$	(52,857	)
Balances at December 31, 2018		11,477,200	$	245,515	$	(248,174	)	$	(2,659	)
Net income		—		—		(54,336	)		(54,336	)
Balances at March 31, 2019		11,477,200	$	245,515	$	(302,510	)	$	(56,995	)

The accompanying footnotes are an integral part of these unaudited condensed financial statements.

5 

CANFIELD MEDICAL SUPPLY, INC.

CONDENSED STATEMENTS OF CASH FLOWS

(Unaudited)

	Three months ended			Three months ended
	March 31, 2019			March 31, 2018
Cash Flows From Operating Activities:
Net income (loss)	$	(54,336	)	$	20,008
Adjustments to reconcile net loss to net cash provided by operating activities:
(Gain) loss on disposal of fixed assets		4,916			(5,249	)
Depreciation		11,210			12,633
Changes in current assets and liabilities
(Increase) decrease in accounts receivable		10,377			(97,092	)
(Increase) decrease in inventory		16,732			(9,666	)
Increase in accounts payable and accrued liabilities		35,684			104,008
Net cash provided by operating activities		24,583			24,642
Cash Flows From Investing Activities:
Proceeds from sale of fixed assets		758			5,389
Purchases of property and equipment		(7,364	)		(12,752	)
Net cash (used for) investing activities		(6,606	)		(7,363	)
Cash Flows From Financing Activities:
Net payments on line of credit		(1,966	)		(1,853	)
Payments on long-term debt		(3,161	)		(3,139	)
Net cash (used for) financing activities		(5,127	)		(4,992	)
Net Increase in Cash		12,850			12,287
Cash At The Beginning Of The Period		6,980			17,921
Cash At The End Of The Period	$	19,830		$	30,208
Supplemental Disclosures
Cash paid for interest	$	1,342		$	1,194
Cash paid for income taxes	$	—		$	—
Schedule of Non-Cash Investing and Financing Activities
Recording of lease liability and right-of-use asset	$	43,677		$	—
Amortization of right-of-use asset	$	6,239		$	—

The accompanying footnotes are an integral part of these unaudited condensed financial statements.

6 

CANFIELD MEDICAL SUPPLY, INC.

CONDENSED NOTES TO FINANCIAL STATEMENTS

For the Three Months Ended March 31, 2019 and 2018 (Unaudited)

NOTE 1. ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Canfield Medical Supply, Inc. (the “Company”), was incorporated in the State of Ohio on September 3, 1992, and changed domicile to Colorado on April 18, 2012. The Company is in the business of home health services, primarily the selling of durable medical equipment and medical supplies to the public, nursing homes, hospitals and other end users.

The accompanying financial statements have been prepared by the Company without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows for the three months ended March 31, 2019 and 2018 have been made.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these financial statements be read in conjunction with the financial statements and notes thereto included in the Company’s December 31, 2018 audited financial statements. The results of operations for the period ended March 31, 2019 are not necessarily indicative of the operating results for the full year.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and cash equivalents

The Company considers all highly liquid investments with an original maturity of three months or less as cash equivalents.

Accounts receivable

The majority of the Company’s revenues are received from Medicare, Medicaid, and private insurance companies. As such, the Company records revenues at allowable amounts, net of estimated allowances and discounts based on contracted prices and historical collection rates. The Company reviews accounts receivable periodically for collectability and establishes an allowance for doubtful accounts and records bad debt expense when deemed necessary. At March 31, 2019 and December 31, 2018, the Company has determined that no allowance for doubtful accounts is necessary.

7 

CANFIELD MEDICAL SUPPLY, INC.

CONDENSED NOTES TO FINANCIAL STATEMENTS

For the Three Months Ended March 31, 2019 and 2018 (Unaudited)

NOTE 1. ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued):

Property and equipment

Property and equipment are recorded at cost and depreciated under straight line methods over each item's estimated useful life.

Inventory

The Company carries inventory of durable medical equipment and medical supplies for resale.  Inventory is accounted for on a first–in first-out basis.

Revenue recognition

It is the Company’s policy that revenues from product sales is recognized in accordance with ASC 606 "Revenue Recognition."  Five basic steps must be followed before revenue can be recognized; (1) Identifying the contract(s) with a customer that creates enforceable rights and obligations; (2) Identifying the performance obligations in the contract, such as promising to transfer goods or services to a customer; (3) Determining the transaction price, meaning the amount of consideration in a contract to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer; (4) Allocating the transaction price to the performance obligations in the contract, which requires the company to allocate the transaction price to each performance obligation on the basis of the relative standalone selling prices of each distinct good or services promised in the contract; and (5) Recognizing revenue when (or as) the entity satisfies a performance obligation by transferring a promised good or service to a customer.  The amount of revenue recognized is the amount allocated to the satisfied performance obligation.  For sales of our Company products, a purchase arrangement is evidenced by a written order, with delivery considered as made after physical customer acceptance. Although rare, defective products may be returned, with other return issues considered on a case by case basis. Services such as periodic scheduled deliveries are contracted in writing, and generally billed monthly. Any service revenue earned by the Company for services such as safety and set up consulting or claims processing is recorded after the service is performed. Rental of durable home medical equipment is evidenced by written contract, with revenue recognized when rent is earned

Advertising costs

Advertising costs are expensed as incurred. The Company had advertising costs during the three months ended March 31, 2019 and 2018 of $704 and $4,293, respectively.

Income tax

The Company accounts for income taxes pursuant to ASC 740. Under ASC 740, deferred taxes are provided for using the liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss carryforwards and deferred tax liabilities are

recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

8 

CANFIELD MEDICAL SUPPLY, INC.

CONDENSED NOTES TO FINANCIAL STATEMENTS

For the Three Months Ended March 31, 2019 and 2018 (Unaudited)

NOTE 1. ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued):

Net income (loss) per share

The net income (loss) per share is computed by dividing the net income (loss) by the weighted average number of shares of common outstanding. Warrants, stock options, and common stock issuable upon the conversion of the Company's preferred stock (if any), are not included in the computation if the effect would be anti-dilutive and would increase the earnings or decrease loss per share.

There were no potentially dilutive debt or equity instruments issued or outstanding during the three months ended March 31, 2019 or 2018.

Financial Instruments

The carrying value of the Company’s financial instruments, as reported in the accompanying balance sheets, approximates fair value.

Concentrations

Financial instruments that potentially subject the Company to concentrations of credit risk include cash and cash equivalents. The Company places its cash and cash equivalents at well-known financial institutions, where at times, such balances may exceed FDIC insurance limits.

The Company receives a significant amount of its revenues in reimbursements from Medicare and Medicaid thru competitive bidding processes. There is no guarantee that the Company will be selected as a winning contract supplier under future bidding rounds.

9 

CANFIELD MEDICAL SUPPLY, INC.

CONDENSED NOTES TO FINANCIAL STATEMENTS

For the Three Months Ended March 31, 2019 and 2018 (Unaudited)

NOTE 1.  ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued):

Long-Lived Assets

In accordance with ASC 350, the Company regularly reviews the carrying value of intangible and other long-lived assets for the existence of facts or circumstances, both internally and externally, that suggest impairment. If impairment testing indicates a lack of recoverability, an impairment loss is recognized by the Company if the carrying amount of a long-lived asset exceeds its fair value.

Products and services, geographic areas and major customers

The Company’s business of medical supply sales constitutes one operating segment. All revenues each year were domestic and to external customers.

Leases

In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02, “Lease (Topic 842),” a new lease standard requiring lessees to recognize lease assets and lease liabilities for most leases classified as operating leases under previous U.S. GAAP. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset (“ROU” asset) representing its right to use the underlying asset for the lease term. The guidance is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company has adopted this standard effective January 1, 2019. The Company elected the optional transition method that permits adoption of the new standard prospectively, as of the effective date, without adjusting comparative periods presented. See Note 6 for disclosure required by ASC 842.

NOTE 2.  EQUIPMENT

Fixed assets are comprised of office equipment, vehicles, and the wheelchair and hospital bed rental pool, which consists of wheelchairs and hospital beds rented to customers over the shorter of the 13-month rental period mandated by Medicaid and Medicare, or the period over which the customer requires use of the wheelchair or hospital bed. At the end of the use period, the wheelchair or hospital bed is transferred to the customer. Depreciation is computed over the estimated useful life of the assets, ranging from 13 months to 7 years, on the straight-line basis. Depreciation expense for the three months ended March 31, 2019 and 2018 was $11,210 and $12,633, respectively. Accumulated depreciation totaled $88,664 and $92,907 at March 31, 2019 and December 31, 2018, respectively.

NOTE 3.  LINE OF CREDIT

At March 31, 2019 and December 31, 2018, the Company owed a bank $64,215 and $66,181, respectively, under a revolving line of credit. The line of credit is secured by all Company assets, is capped at $100,000, is due on demand, and bears interest at variable rates approximating 7% on average . Interest expense under the note approximated $1,202 and $980 during the three months ended March 31, 2019 and 2018, respectively.  During the three months ended March 31, 2019 and 2018, the Company made net principal payments of $1,966 and $1,853, respectively.

10 

CANFIELD MEDICAL SUPPLY, INC.

CONDENSED NOTES TO FINANCIAL STATEMENTS

For the Three Months Ended March 31, 2019 and 2018 (Unaudited)

NOTE 4.  LONG-TERM DEBT

Long-term debt consists of the following vehicle loans, which are collateralized by their underlying vehicles with net carrying values exceeding the outstanding loan amounts:

	March 31, 2019			December 31, 2018
3.53% installment note payable $352 monthly,  including interest, through July 2019	$	1,746		$	2,782
3.79% installment note payable $299 monthly, including interest, through July 2021		7,442			8,532
2.99% installment note payable $350 monthly, including interest, through August 2019		1,390			2,425
		10,578			13,739
Less principal due within one year		(5,926	)		(8,241	)
TOTAL LONG-TERM DEBT	$	4,652		$	5,498

NOTE 5.  COMMON STOCK

In July 2018, the Company received net proceeds of $2,000 from the sale of 200,000 shares of no-par value common stock at $0.10 per share.     

11 

CANFIELD MEDICAL SUPPLY, INC.

CONDENSED NOTES TO FINANCIAL STATEMENTS

For the Three Months Ended March 31, 2019 and 2018 (Unaudited)

NOTE 6.  LEASE COMMITMENTS

The Company rents office space under a non-cancellable lease through September 2020 with monthly payments of approximately $2,292. Pursuant to ASC 842, an operating lease right-of-use (“ROU”) asset and liability were recognized at January 1, 2019 based on the present value of lease payments over the remaining lease term. The ROU asset represents the Company’s right to use the underlying office space asset for the lease term, and the lease liability represents the Company’s obligation to make lease payments arising from the lease. Generally, the implicit rate of interest in arrangements is not readily determinable and the Company utilizes its incremental borrowing rate in determining the present value of lease payments. The operating lease ROU asset includes any lease payments made and excludes lease incentives. The Company recognized $6,900 in lease expense during the three months ended March 31, 2018.

The components of lease expense and supplemental information related to lease for the three months ended March 31, 2019 are as follows:

Remaining lease term at March 31, 2019 (in years)	1.5
Discount rate	5%

	Three Months Ended March 31, 2019
Operating lease expense	$	6,900
Cash paid for amounts included in measurement of lease liability	$	6,900

 The supplemental balance sheet information related to leases for the period is as follows:

Right-of-Use Asset
ROU Asset, January 1, 2019	$	43,667
Amortization of ROU Asset		(6,239	)
ROU Asset, March 31, 2019	$	37,438

 Maturities of the Company’s lease liabilities are as follows:

Year Ending		Payments
	2019	$	20,628
	2020		20,628
	Total lease payments		41,256
	Less: Imputed interest/present value discount		(3,818	)
	Present value of lease liability at March 31, 2019	$	37,438

12 

NOTE 7.  GOING CONCERN

The Company has suffered losses from operations and has working capital and stockholders’ equity deficits. In all likelihood, the Company will be required to make significant future expenditures in connection with marketing efforts along with general administrative expenses. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.

The Company may raise additional capital through the sale of its equity securities, through an offering of debt securities, or through borrowings from financial institutions or related parties. By doing so, the Company hopes to generate sufficient capital to execute its business plan of selling medical supplies on an ongoing basis. Management believes that actions presently being taken to obtain additional funding provide the opportunity for the Company to continue as a going concern.

NOTE 8.  SUBSEQUENT EVENTS

The Company has evaluated subsequent events through the date these financial statements were issued and determined that there are no reportable subsequent events.

13 

Item 2.  Management's Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis should be read in conjunction with the Condensed Financial Statements (unaudited) and Notes to Condensed Financial Statements (unaudited) filed herein.

BUSINESS OVERVIEW

We provide services to the rehabilitation market, which consists primarily of home medical equipment and supplies.  More than 50% of our revenues is derived from the sale and rental of durable home medical equipment including such items as wheeled walkers, manual and power wheelchairs, hospital beds, ramps, bedside commodes, and miscellaneous bathroom equipment.  The balance of our revenue is from the sale of various home medical supplies including diabetic testing, incontinence, ostomy, wound care, and catheter care.  Our emphasis is on helping patients with mobility related limitations, but our overall business is aimed at helping patients remain in their homes instead of having to go to hospitals, rehab centers and other similar facilities.  Most of the equipment and supplies that we sell are prescribed by a physician as part of an overall care plan.

RESULTS OF OPERATION FOR THE THREE MONTHS ENDED MARCH 31, 2019 AS COMPARED TO THE THREE MONTHS ENDED MARCH 31, 2018.

Revenues for the three months ended March 31, 2019 were $271,955 as compared to revenues of $344,624 for the three months ended March 31, 2018.  The $72,669 decrease in sales is due to a decrease in our complex rehab powerchair and wheelchairs sold. Cost of goods sold for the three months ended March 31, 2019 were $132,395 as compared to cost of goods sold for the three months ended March 31, 2018 of $170,176.  The $37,781 decrease in cost of goods sold for the three month period ended March 31, 2019 is primarily due to our decreased sales, and as our sales decreased, our cost for those sales correspondingly decreased. Our gross profit for the three months ended March 31, 2019 was $139,560, as compared to gross profit of $174,448 for the three month period ended March 31, 2018.

Operating expenses for the three months ended March 31, 2019 were $187,638 as compared to $158,495 for the three months ended March 31, 2018. The $29,143 increase in our operating expenses was a result of an increase in our general and administrative expenses during the period related to the costs of being a public company, as well as a $17,054 increase in our salaries and wages. The net loss for the three months ended March 31, 2019 was $54,336 as compared to a net income of $20,008 for the three months ended March 31, 2018. The change in net income to net loss is due to our decrease in revenue coupled with our increase in operating expenses during the period.

14 

LIQUIDITY AND CAPITAL RESOURCES

As of March 31, 2019, we had total assets of $421,954, and as of December 31, 2018, we had total assets of $408,295.

Net cash provided by operating activities during the three months ended March 31, 2019 was $24,583 as compared to net cash provided by operating activities for the three months ended March 31, 2018 of 24,642. The primary reasons for the change in cash provided by operating activities was the change from a net income of $20,008 to a net loss of ($54,336), which was offset by significant decreases in accounts receivable and accounts payable.

Net cash used for investing activities during the three months ended March 31, 2019 was ($6,606). In comparison, during the three months ended March 31, 2018, the net cash used for investing activities was ($7,363). We had $758 of proceeds from the sale of fixed assets during the three month period ended March 31, 2019, as compared to $5,389 of proceeds from the sale of fixed assets during the three month period ended March 31, 2018. Additionally, we had $7,364 used for the purchase of property and equipment during the three month period ended March 31, 2019, as compared to $12,752 used for the purchase of property and equipment during the three month period ended March 31, 2018.

Net cash used for financing activities during the three months ended March 31, 2019 was ($5,127) as compared to ($4,991) used for financing activities for the three month period ended March 31, 2018.  Payments of $5,127 were made towards the Company’s lines of credit and long term debt during the three months ended March 31, 2019, as compared to $4,992 of payments made on the Company’s lines of credit and long term debt during the three months ended March 31, 2018.

15 

CONTRACTUAL OBLIGATIONS

None.

OFF-BALANCE SHEET ARRANGEMENTS

We do not have any off-balance sheet arrangements (as that term is defined in Item 303 of Regulation S-K) that are reasonably likely to have a current or future material effect on our financial condition, revenue or expenses, results of operations, liquidity, capital expenditures or capital resources.

Item 3.  Quantitative and Qualitative Disclosures About Market Risk. 

Not applicable.

Item 4.  Controls and Procedures.

Evaluation of Disclosure Controls and Procedures.

We maintain disclosure controls and procedures (as defined in Rule 13a-l5(e) under the Exchange Act) that are designed to ensure that information that would be required to be disclosed in Exchange Act reports is recorded, processed, summarized and reported within the time period specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including to our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Our management, under the supervision and with the participation of our CEO and Chief Financial Officer ("CFO"), has evaluated the effectiveness of our disclosure controls and procedures as defined in SEC Rules 13a-15(e) and 15d-15(e) as of the end of the period covered by this report. Based on such evaluation, management identified deficiencies that were determined to be a material weakness.

Changes in Internal Control over Financial Reporting.

No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

16 

PART II – OTHER INFORMATION

Item 1.    Legal Proceedings.

None.

Item 1A.  Risk Factors.

Not applicable.

Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3.    Defaults Upon Senior Securities.

None.

Item 4.    Mine Safety Disclosures.

Not applicable.

Item 5.    Other Information.

None.

Item 6.    Exhibits.

(a)  Exhibits required by Item 601 of Regulation S-K.

Exhibits Description

31.1 Certification of CEO and Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) - Filed herewith electronically

31.2 Certification of CFO and Principal Financial and Accounting Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) - Filed herewith electronically

32.1 Certification of CEO and Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 - Filed herewith electronically

32.2 Certification of CFO and Principal Financial and Accounting Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 - Filed herewith electronically

101 XBRL Exhibits

17 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		CANFIELD MEDICAL SUPPLY, INC.
Date:  May 20, 2019	By:	/s/ Michael J. West
		Michael J. West, President and CEO (Principal Executive Officer)
Date:  May 20, 2019	By:	/s/ Stephen H. West
		Stephen H. West, CFO (Principal Financial Officer and Principal Accounting Officer)

EX-31.1

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Michael J. West, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Canfield Medical Supply, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in the Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

(a)  Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within the registrant, particularly during the period in which this report is being prepared;

(b)  Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)  Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)  Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b)  Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:  May 20, 2019

/s/ Michael J. West

Michael J. West

Chief Executive Officer

(Principal Executive Officer)

EX-31.2

Exhibit 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Stephen H. West, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Canfield Medical Supply, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in the Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

(a)  Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within the registrant, particularly during the period in which this report is being prepared;

(b)  Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)  Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)  Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b)  Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:  May 20, 2019

/s/ Stephen H. West

Stephen H. West

Chief Financial Officer

(Principal Financial Officer and

Principal Accounting Officer)

EX-32.1

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

 PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Form 10-Q of Canfield Medical Supply, Inc., a company duly formed under the laws of Colorado (the "Company"), for the quarter ended March 31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Michael J. West, President (Chief Executive Officer) of the Company, hereby certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of his knowledge, that:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date:  May 20, 2019	/s/ Michael J. West
	Michael J. West Chief Executive Officer (Principal Executive Officer)

This certification accompanies this Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

A signed original of this written statement required by Section 906 has been provided to Canfield Medical Supply, Inc. and will be retained by Canfield Medical Supply, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2

Exhibit 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

 PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Form 10-Q of Canfield Medical Supply, Inc., a company duly formed under the laws of Colorado (the "Company"), for the quarter ended March 31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Stephen H. West, Chief Financial Officer of the Company, hereby certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of his knowledge, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date:  May 20, 2019	/s/ Stephen H. West
	Stephen H. West Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) (Principal Executive Officer)

This certification accompanies this Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

A signed original of this written statement required by Section 906 has been provided to Canfield Medical Supply, Inc. and will be retained by Canfield Medical Supply, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

XML

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2019	May 20, 2019
Document And Entity Information
Entity Registrant Name	CANFIELD MEDICAL SUPPLY, INC.
Entity Central Index Key	0001553788
Document Type	10-Q
Document Period End Date	Mar. 31, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	true
Entity Small Business	true
Entity Ex Transition Period	true
Entity Common Stock, Shares Outstanding		11,477,200
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2019

XML

CONDENSED BALANCE SHEETS (UNAUDITED) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Current Assets
Cash	$ 19,830	$ 6,980
Accounts receivable	290,616	300,993
Inventory	24,963	41,695
Total Current Assets	335,409	349,668
Other Assets
Right-of-use asset	37,438	0
Equipment, net of accumulated depreciation of $88,664 and $92,907	49,107	58,627
Total Other Assets	86,545	58,627
Total Assets	421,954	408,295
Current Liabilities
Accounts payable and accrued liabilities	366,718	331,034
Line of credit	64,215	66,181
Current portion of long-term debt	5,926	8,241
Total Current Liabilities	436,859	405,456
Long-Term Liabilities
Lease liability	37,438	0
Long-term debt	4,652	5,498
Total Long-Term Liabilities	42,090	5,498
Total Liabilities	478,949	410,954
Stockholders' Equity (Deficit)
Preferred stock, no par value; 5,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock, no par value; 100,000,000 shares authorized; 11,477,200 shares issued and outstanding	245,515	245,515
Accumulated deficit	(302,510)	(248,174)
Total Stockholders' Equity (Deficit)	(56,995)	(2,659)
Total Liabilities and Stockholders' Equity (Deficit)	$ 421,954	$ 408,295

XML

CONDENSED BALANCE SHEETS (Parenthetical) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Preferred stock, no par value	$ 0	$ 0
Preferred stock, authorized shares	5,000,000	5,000,000
Preferred stock, issued shares	0	0
Preferred stock, outstanding shares	0	0
Common stock, no par value	$ 0	$ 0
Common stock, authorized shares	100,000,000	100,000,000
Common stock, issued shares	11,477,200	11,477,200
Common stock, outstanding shares	11,477,200	11,477,200
Accumulated depreciation	$ 88,664	$ 92,907

XML

CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Income Statement [Abstract]
Sales (net of returns)	$ 271,955	$ 344,624
Cost of goods sold	132,395	170,176
Gross profit	139,560	174,448
Operating expenses:
Salaries and wages	88,821	71,767
Professional fees	35,355	31,265
Depreciation	11,210	12,633
Other selling, general and administrative	52,252	42,830
Total operating expenses	187,638	158,495
Income (loss) from operations	(48,078)	15,953
Other income (expense):
Interest expense	(1,342)	(1,194)
Gain (Loss) on sale of fixed assets	(4,916)	5,249
Total other income (expense)	(6,258)	4,055
Income (loss) before provision for income taxes	(54,336)	20,008
Provision for income tax	0	0
Net income (loss)	$ (54,336)	$ 20,008
Net income (loss) per share (basic and fully diluted)	$ (0.00)	$ 0.00
Weighted average number of common shares outstanding	11,427,200	11,427,200

XML

CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (UNAUDITED) - USD ($)	Common Stock	Accumulated Deficit	Total
Beginning Balance at Dec. 31, 2017	$ 243,515	$ (316,380)	$ (72,865)
Beginning Balance, in Shares at Dec. 31, 2017	11,277,200
Net income		20,008	20,008
Ending Balance at Mar. 31, 2018	$ 243,515	(296,372)	(52,857)
Ending Balance, in Shares at Mar. 31, 2018	11,277,200
Beginning Balance at Dec. 31, 2018	$ 245,515	(248,174)	(2,659)
Beginning Balance, in Shares at Dec. 31, 2018	11,477,200
Net income		(54,336)	(54,336)
Ending Balance at Mar. 31, 2019	$ 245,515	$ (302,510)	$ (56,995)
Ending Balance, in Shares at Mar. 31, 2019	11,477,200

XML

CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Cash Flows From Operating Activities:
Net income (loss)	$ (54,336)	$ 20,008
Adjustments to reconcile net loss to net cash provided by operating activities:
(Gain) loss on disposal of fixed assets	4,916	(5,249)
Depreciation	11,210	12,633
Changes in current assets and liabilities:
(Increase) decrease in accounts receivable	10,377	(97,092)
(Increase) decrease in inventory	16,732	(9,666)
Increase in accounts payable and accrued liabilities	35,684	104,008
Net cash provided by operating activities	24,583	24,642
Cash Flows From Investing Activities:
Proceeds from sale of fixed assets	758	5,389
Purchase of property and equipment	(7,364)	(12,752)
Net cash (used for) investing activities	(6,606)	(7,363)
Cash Flows From Financing Activities:
Net payments on line of credit	(1,966)	(1,853)
Payments on long-term debt	(3,161)	(3,139)
Net cash (used for) financing activities	(5,127)	(4,992)
Net Increase in Cash	12,850	12,287
Cash At The Beginning Of The Period	6,980	17,921
Cash At The End Of The Period	19,830	30,208
Supplemental Disclosure
Cash paid for interest	1,342	1,194
Cash paid for income taxes	0	0
Schedule of Non-Cash Investing and Financing Activities
Recording of lease liability and right-of-use asset	43,677	0
Amortization of right-of-use asset	$ 6,239	$ 0

XML

ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3 Months Ended

Mar. 31, 2019

Accounting Policies [Abstract]

ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 1. ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Canfield Medical Supply, Inc. (the “Company”), was incorporated in the State of Ohio on September 3, 1992, and changed domicile to Colorado on April 18, 2012. The Company is in the business of home health services, primarily the selling of durable medical equipment and medical supplies to the public, nursing homes, hospitals and other end users.

The accompanying financial statements have been prepared by the Company without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows for the three months ended March 31, 2019 and 2018 have been made.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these financial statements be read in conjunction with the financial statements and notes thereto included in the Company’s December 31, 2018 audited financial statements. The results of operations for the period ended March 31, 2019 are not necessarily indicative of the operating results for the full year.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and cash equivalents

The Company considers all highly liquid investments with an original maturity of three months or less as cash equivalents.

Accounts receivable

The majority of the Company’s revenues are received from Medicare, Medicaid, and private insurance companies. As such, the Company records revenues at allowable amounts, net of estimated allowances and discounts based on contracted prices and historical collection rates. The Company reviews accounts receivable periodically for collectability and establishes an allowance for doubtful accounts and records bad debt expense when deemed necessary. At March 31, 2019 and December 31, 2018, the Company has determined that no allowance for doubtful accounts is necessary.

Property and equipment

Property and equipment are recorded at cost and depreciated under straight line methods over each item's estimated useful life.

Inventory

The Company carries inventory of durable medical equipment and medical supplies for resale.  Inventory is accounted for on a first–in first-out basis.

Revenue recognition

It is the Company’s policy that revenues from product sales is recognized in accordance with ASC 606 "Revenue Recognition."  Five basic steps must be followed before revenue can be recognized; (1) Identifying the contract(s) with a customer that creates enforceable rights and obligations; (2) Identifying the performance obligations in the contract, such as promising to transfer goods or services to a customer; (3) Determining the transaction price, meaning the amount of consideration in a contract to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer; (4) Allocating the transaction price to the performance obligations in the contract, which requires the company to allocate the transaction price to each performance obligation on the basis of the relative standalone selling prices of each distinct good or services promised in the contract; and (5) Recognizing revenue when (or as) the entity satisfies a performance obligation by transferring a promised good or service to a customer.  The amount of revenue recognized is the amount allocated to the satisfied performance obligation.  For sales of our Company products, a purchase arrangement is evidenced by a written order, with delivery considered as made after physical customer acceptance. Although rare, defective products may be returned, with other return issues considered on a case by case basis. Services such as periodic scheduled deliveries are contracted in writing, and generally billed monthly. Any service revenue earned by the Company for services such as safety and set up consulting or claims processing is recorded after the service is performed. Rental of durable home medical equipment is evidenced by written contract, with revenue recognized when rent is earned

Advertising costs

Advertising costs are expensed as incurred. The Company had advertising costs during the three months ended March 31, 2019 and 2018 of $704 and $4,293, respectively.

Income tax

The Company accounts for income taxes pursuant to ASC 740. Under ASC 740, deferred taxes are provided for using the liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss carryforwards and deferred tax liabilities are

recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

Net income (loss) per share

The net income (loss) per share is computed by dividing the net income (loss) by the weighted average number of shares of common outstanding. Warrants, stock options, and common stock issuable upon the conversion of the Company's preferred stock (if any), are not included in the computation if the effect would be anti-dilutive and would increase the earnings or decrease loss per share.

There were no potentially dilutive debt or equity instruments issued or outstanding during the three months ended March 31, 2019 or 2018.

Financial Instruments

The carrying value of the Company’s financial instruments, as reported in the accompanying balance sheets, approximates fair value.

Concentrations

Financial instruments that potentially subject the Company to concentrations of credit risk include cash and cash equivalents. The Company places its cash and cash equivalents at well-known financial institutions, where at times, such balances may exceed FDIC insurance limits.

The Company receives a significant amount of its revenues in reimbursements from Medicare and Medicaid thru competitive bidding processes. There is no guarantee that the Company will be selected as a winning contract supplier under future bidding rounds.

Long-Lived Assets

In accordance with ASC 350, the Company regularly reviews the carrying value of intangible and other long-lived assets for the existence of facts or circumstances, both internally and externally, that suggest impairment. If impairment testing indicates a lack of recoverability, an impairment loss is recognized by the Company if the carrying amount of a long-lived asset exceeds its fair value.

Products and services, geographic areas and major customers

The Company’s business of medical supply sales constitutes one operating segment. All revenues each year were domestic and to external customers.

Leases

In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02, “Lease (Topic 842),” a new lease standard requiring lessees to recognize lease assets and lease liabilities for most leases classified as operating leases under previous U.S. GAAP. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset (“ROU” asset) representing its right to use the underlying asset for the lease term. The guidance is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company has adopted this standard effective January 1, 2019. The Company elected the optional transition method that permits adoption of the new standard prospectively, as of the effective date, without adjusting comparative periods presented. See Note 6 for disclosure required by ASC 842.

XML

EQUIPMENT

3 Months Ended

Mar. 31, 2019

Property, Plant and Equipment [Abstract]

EQUIPMENT

NOTE 2.  EQUIPMENT

Fixed assets are comprised of office equipment, vehicles, and the wheelchair and hospital bed rental pool, which consists of wheelchairs and hospital beds rented to customers over the shorter of the 13-month rental period mandated by Medicaid and Medicare, or the period over which the customer requires use of the wheelchair or hospital bed. At the end of the use period, the wheelchair or hospital bed is transferred to the customer. Depreciation is computed over the estimated useful life of the assets, ranging from 13 months to 7 years, on the straight-line basis. Depreciation expense for the three months ended March 31, 2019 and 2018 was $11,210 and $12,633, respectively. Accumulated depreciation totaled $88,664 and $92,907 at March 31, 2019 and December 31, 2018, respectively.

XML

LINE OF CREDIT

3 Months Ended

Mar. 31, 2019

Debt Disclosure [Abstract]

LINE OF CREDIT

NOTE 3.  LINE OF CREDIT

At March 31, 2019 and December 31, 2018, the Company owed a bank $64,215 and $66,181, respectively, under a revolving line of credit. The line of credit is secured by all Company assets, is capped at $100,000, is due on demand, and bears interest at variable rates approximating 7% on average . Interest expense under the note approximated $1,202 and $980 during the three months ended March 31, 2019 and 2018, respectively.  During the three months ended March 31, 2019 and 2018, the Company made net principal payments of $1,966 and $1,853, respectively.

XML

LONG-TERM DEBT

3 Months Ended

Mar. 31, 2019

Debt Disclosure [Abstract]

LONG-TERM DEBT

NOTE 4.  LONG-TERM DEBT

Long-term debt consists of the following vehicle loans, which are collateralized by their underlying vehicles with net carrying values exceeding the outstanding loan amounts:

	March 31, 2019			December 31, 2018
3.53% installment note payable $352 monthly,  including interest, through July 2019	$	1,746		$	2,782
3.79% installment note payable $299 monthly, including interest, through July 2021		7,442			8,532
2.99% installment note payable $350 monthly, including interest, through August 2019		1,390			2,425
		10,578			13,739
Less principal due within one year		(5,926	)		(8,241	)
TOTAL LONG-TERM DEBT	$	4,652		$	5,498

XML

COMMON STOCK

3 Months Ended

Mar. 31, 2019

Accounting Policies [Abstract]

COMMON STOCK

NOTE 5.  COMMON STOCK

In July 2018, the Company received net proceeds of $2,000 from the sale of 200,000 shares of no-par value common stock at $0.10 per share.  

XML

LEASE COMMITMENTS

3 Months Ended

Mar. 31, 2019

Leases [Abstract]

LEASE COMMITMENTS

NOTE 6.  LEASE COMMITMENTS

The Company rents office space under a non-cancellable lease through September 2020 with monthly payments of approximately $2,292. Pursuant to ASC 842, an operating lease right-of-use (“ROU”) asset and liability were recognized at January 1, 2019 based on the present value of lease payments over the remaining lease term. The ROU asset represents the Company’s right to use the underlying office space asset for the lease term, and the lease liability represents the Company’s obligation to make lease payments arising from the lease. Generally, the implicit rate of interest in arrangements is not readily determinable and the Company utilizes its incremental borrowing rate in determining the present value of lease payments. The operating lease ROU asset includes any lease payments made and excludes lease incentives. The Company recognized $6,900 in lease expense during the three months ended March 31, 2018.

The components of lease expense and supplemental information related to lease for the three months ended March 31, 2019 are as follows:

Remaining lease term at March 31, 2019 (in years)	1.5
Discount rate	5%

	Three Months Ended March 31, 2019
Operating lease expense	$	6,900
Cash paid for amounts included in measurement of lease liability	$	6,900

 The supplemental balance sheet information related to leases for the period is as follows:

Right-of-Use Asset
ROU Asset, January 1, 2019	$	43,667
Amortization of ROU Asset		(6,239	)
ROU Asset, March 31, 2019	$	37,438

 Maturities of the Company’s lease liabilities are as follows:

Year Ending		Payments
	2019	$	20,628
	2020		20,628
	Total lease payments		41,256
	Less: Imputed interest/present value discount		(3,818	)
	Present value of lease liability at March 31, 2019	$	37,438

XML

GOING CONCERN

3 Months Ended

Mar. 31, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

GOING CONCERN

NOTE 7.  GOING CONCERN

The Company has suffered losses from operations and has working capital and stockholders’ equity deficits. In all likelihood, the Company will be required to make significant future expenditures in connection with marketing efforts along with general administrative expenses. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.

The Company may raise additional capital through the sale of its equity securities, through an offering of debt securities, or through borrowings from financial institutions or related parties. By doing so, the Company hopes to generate sufficient capital to execute its business plan of selling medical supplies on an ongoing basis. Management believes that actions presently being taken to obtain additional funding provide the opportunity for the Company to continue as a going concern.

XML

SUBSEQUENT EVENTS

3 Months Ended

Mar. 31, 2019

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE 8.  SUBSEQUENT EVENTS

The Company has evaluated subsequent events through the date these financial statements were issued and determined that there are no reportable subsequent events.

XML

ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

3 Months Ended

Mar. 31, 2019

Accounting Policies [Abstract]

Use of Estimates

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and cash equivalents

Cash and cash equivalents

The Company considers all highly liquid investments with an original maturity of three months or less as cash equivalents.

Accounts receivable

Accounts receivable

The majority of the Company’s revenues are received from Medicare, Medicaid, and private insurance companies. As such, the Company records revenues at allowable amounts, net of estimated allowances and discounts based on contracted prices and historical collection rates. The Company reviews accounts receivable periodically for collectability and establishes an allowance for doubtful accounts and records bad debt expense when deemed necessary. At March 31, 2019 and December 31, 2018, the Company has determined that no allowance for doubtful accounts is necessary.

Property and equipment

Property and equipment

Property and equipment are recorded at cost and depreciated under straight line methods over each item's estimated useful life.

Inventory

Inventory

The Company carries inventory of durable medical equipment and medical supplies for resale.  Inventory is accounted for on a first–in first-out basis.

Revenue recognition

Revenue recognition

It is the Company’s policy that revenues from product sales is recognized in accordance with ASC 606 "Revenue Recognition."  Five basic steps must be followed before revenue can be recognized; (1) Identifying the contract(s) with a customer that creates enforceable rights and obligations; (2) Identifying the performance obligations in the contract, such as promising to transfer goods or services to a customer; (3) Determining the transaction price, meaning the amount of consideration in a contract to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer; (4) Allocating the transaction price to the performance obligations in the contract, which requires the company to allocate the transaction price to each performance obligation on the basis of the relative standalone selling prices of each distinct good or services promised in the contract; and (5) Recognizing revenue when (or as) the entity satisfies a performance obligation by transferring a promised good or service to a customer.  The amount of revenue recognized is the amount allocated to the satisfied performance obligation.  For sales of our Company products, a purchase arrangement is evidenced by a written order, with delivery considered as made after physical customer acceptance. Although rare, defective products may be returned, with other return issues considered on a case by case basis. Services such as periodic scheduled deliveries are contracted in writing, and generally billed monthly. Any service revenue earned by the Company for services such as safety and set up consulting or claims processing is recorded after the service is performed. Rental of durable home medical equipment is evidenced by written contract, with revenue recognized when rent is earned

Advertising costs

Advertising costs

Advertising costs are expensed as incurred. The Company had advertising costs during the three months ended March 31, 2019 and 2018 of $704 and $4,293, respectively.

Income tax

Income tax

The Company accounts for income taxes pursuant to ASC 740. Under ASC 740, deferred taxes are provided for using the liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss carryforwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

Net income (loss) per share

Net income (loss) per share

The net income (loss) per share is computed by dividing the net income (loss) by the weighted average number of shares of common outstanding. Warrants, stock options, and common stock issuable upon the conversion of the Company's preferred stock (if any), are not included in the computation if the effect would be anti-dilutive and would increase the earnings or decrease loss per share.

There were no potentially dilutive debt or equity instruments issued or outstanding during the three months ended March 31, 2019 or 2018.

Financial Instruments

Financial Instruments

The carrying value of the Company’s financial instruments, as reported in the accompanying balance sheets, approximates fair value.

Concentrations

Concentrations

Financial instruments that potentially subject the Company to concentrations of credit risk include cash and cash equivalents. The Company places its cash and cash equivalents at well-known financial institutions, where at times, such balances may exceed FDIC insurance limits.

The Company receives a significant amount of its revenues in reimbursements from Medicare and Medicaid thru competitive bidding processes. There is no guarantee that the Company will be selected as a winning contract supplier under future bidding rounds.

Long-Lived Assets

Long-Lived Assets

In accordance with ASC 350, the Company regularly reviews the carrying value of intangible and other long-lived assets for the existence of facts or circumstances, both internally and externally, that suggest impairment. If impairment testing indicates a lack of recoverability, an impairment loss is recognized by the Company if the carrying amount of a long-lived asset exceeds its fair value.

Products and services, geographic areas and major customers

Products and services, geographic areas and major customers

The Company’s business of medical supply sales constitutes one operating segment. All revenues each year were domestic and to external customers.

Leases

Leases

In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02, “Lease (Topic 842),” a new lease standard requiring lessees to recognize lease assets and lease liabilities for most leases classified as operating leases under previous U.S. GAAP. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset (“ROU” asset) representing its right to use the underlying asset for the lease term. The guidance is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company has adopted this standard effective January 1, 2019. The Company elected the optional transition method that permits adoption of the new standard prospectively, as of the effective date, without adjusting comparative periods presented. See Note 6 for disclosure required by ASC 842.

XML

LONG-TERM DEBT (Tables)

3 Months Ended

Mar. 31, 2019

Debt Disclosure [Abstract]

Schedule of Long Term Debt

Long-term debt consists of the following vehicle loans, which are collateralized by their underlying vehicles with net carrying values exceeding the outstanding loan amounts:

	March 31, 2019			December 31, 2018
3.53% installment note payable $352 monthly,  including interest, through July 2019	$	1,746		$	2,782
3.79% installment note payable $299 monthly, including interest, through July 2021		7,442			8,532
2.99% installment note payable $350 monthly, including interest, through August 2019		1,390			2,425
		10,578			13,739
Less principal due within one year		(5,926	)		(8,241	)
TOTAL LONG-TERM DEBT	$	4,652		$	5,498

XML

LEASE COMMITMENTS (Tables)

3 Months Ended

Mar. 31, 2019

Leases [Abstract]

Components of lease expense and supplemental information related to lease

The components of lease expense and supplemental information related to lease for the three months ended March 31, 2019 are as follows:

Remaining lease term at March 31, 2019 (in years)	1.5
Discount rate	5%

	Three Months Ended March 31, 2019
Operating lease expense	$	6,900
Cash paid for amounts included in measurement of lease liability	$	6,900

Supplemental balance sheet information related to leases

The supplemental balance sheet information related to leases for the period is as follows:

Right-of-Use Asset
ROU Asset, January 1, 2019	$	43,667
Amortization of ROU Asset		(6,239	)
ROU Asset, March 31, 2019	$	37,438

Maturities of lease liabilities

Maturities of the Company’s lease liabilities are as follows:

Year Ending		Payments
	2019	$	20,628
	2020		20,628
	Total lease payments		41,256
	Less: Imputed interest/present value discount		(3,818	)
	Present value of lease liability at March 31, 2019	$	37,438

XML

ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Accounting Policies [Abstract]
Advertising cost	$ 704	$ 4,293
Allowance for doubtful accounts	$ 0		$ 0
Potentially dilutive shares	0	0

XML

EQUIPMENT (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Depreciation	$ 11,210	$ 12,633
Accumulated depreciation	$ 88,664		$ 92,907
Minimum [Member]
Estimated useful life of assets	13 months
Maximum [Member]
Estimated useful life of assets	7 years

XML

LINE OF CREDIT (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Debt Disclosure [Abstract]
Line of credit	$ 64,215		$ 66,181
Secured line of credit	100,000
Interest expense	1,202	$ 980
Repayments of Lines of Credit	$ (1,966)	$ (1,853)

XML

LONG-TERM DEBT (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Long Term Gross	$ 10,578	$ 13,739
Less principal due within one year	(5,926)	(8,241)
Total Long Term debt	4,652	5,498
Long-term Debt One [Member]
Note Payable, monthly installment	352
Long Term Gross	1,746	2,782
Long-term Debt Two [Member]
Note Payable, monthly installment	299
Long Term Gross	7,442	8,532
Long-term Debt Three [Member]
Note Payable, monthly installment	350
Long Term Gross	$ 1,390	$ 2,425

XML

COMMON STOCK (Details Narrative)	3 Months Ended
	Mar. 31, 2019 USD ($) $ / shares shares
Equity [Abstract]
Proceeds from sales of common stock | $	$ 2,000
Number of shares sold for proceeds | shares	200,000
Value of common stock sold (per share) | $ / shares	$ 0.10

XML

LEASE COMMITMENTS (Details)	3 Months Ended
	Mar. 31, 2019 USD ($)
Leases [Abstract]
Remaining lease term (in years)	1 year 6 months
Discount rate	5.00%
Operating lease expense	$ 6,900
Cash paid for amounts included in measurement of lease liability	$ 6,900

XML

LEASE COMMITMENTS (Details 1)	3 Months Ended
	Mar. 31, 2019 USD ($)
Right-of-Use Asset
ROU Asset, at beginning	$ 43,667
Amortization of ROU Asset	(6,239)
ROU Asset, at end	$ 37,438

XML

LEASE COMMITMENTS (Details 2)	Mar. 31, 2019 USD ($)
Leases [Abstract]
2019	$ 20,628
2020	20,628
Total lease payments	41,256
Less: Imputed interest/present value discount	(3,818)
Present value of lease liability	$ 37,438

XML

LEASE COMMITMENTS (Details Narrative)	3 Months Ended
	Mar. 31, 2019 USD ($)
Leases [Abstract]
Office space approximate monthly payment	$ 2,292
Lease expense	$ 6,900